Sleep Disorders

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

Healthy lifestyle choices are an integral part of disease management for patients with narcolepsy who face an increased prevalence of comorbid cardiovascular and metabolic conditions.

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

The vice president of science and medical at Dreem offered his opinion on how the company’s headband device can improve how sleep studies are conducted.

Researchers noted that further examinations are needed of the genetic heterogeneity depression syndromes to test for causal relationships between distinct subtypes of depression and Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

The vice president of science and medical at Dreem discussed how the company’s headband device stacked up against polysomnography for sleep monitoring.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

The vice president of science and medical at Dreem offered an overview of the hardware that makes up the Dreem Headband and how it was developed to monitor sleep.

Notably, the data unveiled a previously unreported link between a positive family history of parkinsonism and dementia, and carbon monoxide poisoning.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

Neurology News Network for the week ending July 25, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

The treatment, marketed as Xywav, becomes the first treatment indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in 15 years.

The affordable device’s accuracy compared to polysomnography may pave the way for a better way to conduct larger scale, longitudinal sleep studies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

A cross-sectional analysis of 2 study cohorts suggests that less rapid eye movement sleep is linked with an increased risk of all-cause mortality, which persisted across different causes of death.